Home > Healthcare > Medical Devices > Diagnostic Devices > Cancer Diagnostics Market

Cancer Diagnostics Market Share

Report ID: GMI2406
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Cancer Diagnostics Market Share

The market is competitive, featuring both major global companies and numerous smaller firms. A key strategy for participants is investing in the development of advanced diagnostic technologies, such as liquid biopsies, next-generation sequencing (NGS), and AI-driven imaging, to enhance accuracy and efficiency. Strategic partnerships with research institutions and healthcare providers are crucial for integrating modern technologies and expanding distribution, enabling companies to address the rising demand for non-invasive and cost-effective diagnostic solutions. Regulatory support and streamlined approval processes further drive innovation and market entry, solidifying the position of firms within the growing market.

Cancer Diagnostics Market Companies

Some of the eminent market participants operating in the cancer diagnostics industry include:

Abbott Laboratories
AB Sciex Pte
Agilent Technologies
Becton, Dickinson and Company
Biocare Medical
Biocartis
Biomerieux
Bio-Rad Laboratories
Danaher Corporation
F-Hoffmann-La Roche
GE Healthcare
Hologic
Johnson & Johnson
Koninklijke Philips
Myriad Genetics
QIAGEN
Siemens Healthineers
Sysmex Corporation
Thermo Fisher Scientific

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

The global cancer diagnostics industry was valued at approximately USD 158.7 billion in 2024 and is estimated to grow at a 9% CAGR from 2025 to 2034, driven by advancements in diagnostic technologies and increasing cancer prevalence.

The liver and lung cancer segment accounted for an 18.4% market share in 2024 and is projected to reach USD 65.5 billion by 2034, fueled by rising incidences of these cancers and advancements in diagnostic methods.

The U.S. cancer diagnostics market is projected to grow significantly, reaching USD 135 billion by 2034, driven by an aging population, lifestyle choices, and environmental exposures.

Key players in the industry include Abbott Laboratories, AB Sciex Pte, Agilent Technologies, Becton, Dickinson and Company, Biocare Medical, Biocartis, Biomerieux, Bio-Rad Laboratories, Danaher Corporation, F-Hoffmann-La Roche, and GE Healthcare.